Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 4/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077172 | 0.93 | KDR (0.52) | KDRNPC1RAB9AFLT1TMPRSS4 | |
| SCHEMBL3189613 | 0.88 | KDR (0.52) | KDRNPC1RAB9ASMN1; SMN2FLT1 | |
| SCHEMBL2075725 | 0.87 | KDR (0.47) | KDRNPC1RAB9ASMN1; SMN2FLT1 | |
| SCHEMBL2079474 | 0.87 | SGMS2 (0.51) | KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2078371 | 0.85 | KDR (0.46) | KDRNPC1RAB9ASMN1; SMN2FLT1 | |
| SCHEMBL2078831 | 0.80 | NPC1 (0.45) | KDRNPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL2077372 | 0.80 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1 | |
| SCHEMBL2077184 | 0.79 | ALDH1A1 (0.52) | KDRNPC1RAB9AFLT1TMPRSS4 | |
| SCHEMBL2078168 | 0.79 | KDR (0.52) | KDRNPC1RAB9AFLT1TMPRSS4 | |
| SCHEMBL2077519 | 0.79 | KDR (0.48) | KDRNPC1RAB9ASMN1; SMN2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | claimed |
| US-7659298-B2 | 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-02-09 | — | — | US | claimed |
| EP-1699454-B1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-08-05 | — | — | EP | claimed |
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | claimed |
| EP-1699454-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-09-13 | — | — | EP | claimed |
| WO-2005060959-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | WO | claimed |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7659298-B2 | 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-02-09 | — | — | US | disclosed |
| EP-1699454-B1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1699454-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005060959-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KDR 1540/4885NPC1 1064/4885RAB9A 2920/4885 |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KDR 1540/4885NPC1 1064/4885RAB9A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.